Drilldown: Medicines
Use the filters below to narrow your results.
generic:
None (1) ·
Asenapine (1) ·
Brivaracetam (1) ·
Cannabidiol (1) ·
Cenobamate (1) ·
Chlorpromazine (1) ·
Clobazam (1) ·
Clozapine (1) ·
Droperidol (1) ·
Eslicarbazepine (1) ·
Ethosuximide (1) ·
Felbamate (1) ·
Fenfluramine (1) ·
Fluphenazine (1) ·
Fosphenytoin (1) ·
Iloperidone (1) ·
Lacosamide (1) ·
Loxapine (1) ·
Lurasidone (1) ·
Molindone (1) ·
Paliperidone (1) ·
Perampanel (1) ·
Perphenazine (1) ·
Phenobarbital (1) ·
Phenytoin (1) ·
Pimozide (1) ·
Prochlorperazine (1) ·
Rufinamide (1) ·
Stiripentol (1) ·
Thioridazine (1) ·
Thiothixene (1) ·
Tiagabine (1) ·
Trifluoperazine (1) ·
Valproic acid (1) ·
Vigabatrin (1) ·
Ziprasidone (1) ·
Zonisamide (1)
brand:
Aptiom (1) ·
Banzel (1) ·
Briviact (1) ·
Cerebyx (1) ·
Clozaril (1) ·
Compazine (1) ·
Depakote (1) ·
Diacomit (1) ·
Dilantin (1) ·
Epidiolex (1) ·
Fanapt (1) ·
Felbatol (1) ·
Fintepla (1) ·
Fycompa (1) ·
Gabitril (1) ·
Geodon (1) ·
Inapsine (1) ·
Invega (1) ·
Latuda (1) ·
Loxitane (1) ·
Luminal (1) ·
Mellaril (1) ·
Moban (1) ·
Navane (1) ·
Onfi (1) ·
Orap (1) ·
Prolixin (1) ·
Rexulti (1) ·
Sabril (1) ·
Saphris (1) ·
Stelazine (1) ·
Thorazine (1) ·
Trilafon (1) ·
Vimpat (1) ·
Xcopri (1) ·
Zarontin (1) ·
Zonegran (1)
classes: (Click arrow to add another value)
mechanism:
AMPA receptor antagonist (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
GABA enhancer; sodium channel blocker; histone deacetylase inhibitor (1) ·
GABA reuptake inhibitor (GAT-1 blocker) (1) ·
GABAA positive allosteric modulator (1) ·
GABAA positive allosteric modulator; lactate dehydrogenase inhibitor (1) ·
GABAA potentiator and direct activator (1) ·
Irreversible GABA-T inhibitor (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Multiple mechanisms; GPR55 antagonist; TRPV1 agonist (1) ·
NMDA antagonist; GABAA potentiator (1) ·
Partial agonist at D2 and 5HT1A. Antagonist at 5HT2A, α1A, α1B, α2C. More potent 5HT2A antagonism, 5HT1A partial agonism, and α1 antagonism (relative to D2 partial agonism) than aripiprazole, proposed to reduce akathisia and enhance affective/cognitive effects. (1) ·
Phenothiazine D2 antagonist (5) ·
Prodrug of phenytoin; sodium channel blocker (1) ·
Serotonin releaser; sigma-1 agonist (1) ·
Slow-inactivation sodium channel enhancer; CRMP-2 ligand (1) ·
Sodium channel blocker (2) ·
Sodium channel blocker; GABAA positive allosteric modulator (1) ·
Sodium channel modulator (1) ·
Sodium/T-type calcium channel blocker; carbonic anhydrase inhibitor (1) ·
SV2A ligand (higher affinity than levetiracetam) (1) ·
T-type calcium channel blocker (1) ·
Thioxanthene D2 antagonist (1)
uses:
None (36) ·
Schizophrenia (FDA-approved 2015). Adjunctive treatment of major depressive disorder (2015). '''Agitation associated with dementia due to Alzheimer disease''' (FDA-approved May 2023, first agent specifically approved for this problem). Investigational for PTSD (combined with sertraline). (1)
starting dose:
preparations:
duration:
halflife:
Showing below up to 37 results in range #1 to #37.